Trial Profile
A Phase 2 Study to Evaluate the Safety and Efficacy of Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 14 Feb 2023 Status changed from active, no longer recruiting to completed.
- 13 Jun 2022 Planned End Date changed from 1 Jun 2021 to 1 Jun 2023.
- 13 Jun 2022 Planned primary completion date changed from 1 Feb 2020 to 1 Dec 2022.